Abstract
High-dose chemotherapy with autologous hematopoietic stem cell reconstitution is efficacious in the treatment of multiple myeloma. The various preparative regimens, sources of hematopoietic stem cells, and post-transplant immunomodulation are discussed. Tandem autotransplantation following intravenous melphalan chemotherapy has low morbidity and mortality even in patients with refractory disease. The most encouraging results are observed in patients undergoing high-dose chemotherapy with less prior treatment, lower tumor mass, and sensitive disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
